Benzinga - by Avi Kapoor, Benzinga Staff Writer.
Shares of VirTra, Inc. (NASDAQ: VTSI) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter results.
VirTra posted GAAP earning of 25 cents per share, beating market estimates of 17 cents per share. The company’s quarterly sales came in at $10.100 million versus expectation of $9.373 million, according to data from Benzinga Pro.
VirTra shares jumped 20% to $11.45 in pre-market trading
Here are some other stocks moving in pre-market trading.
Gainers
- XTI Aerospace, Inc. (NASDAQ: XTIA) rose 121.9% to $4.57 in pre-market trading after jumping 19% on Monday.
- Kidpik Corp. (NASDAQ: PIK) gained 70.8% to $7.43 in pre-market trading. Kidpik and Nina Footwear announced entry into definitive merger agreement.
- MSP Recovery, Inc. (NASDAQ: LIFW) gained 49.9% to $0.9999 in pre-market trading after a 13G filing showed Palantir Technologies reported a 6.5% stake in the company as of March 22, 2024.
- Serina Therapeutics, Inc. (NASDAQ: ZPTA) shares gained 23.5% to $7.04 in pre-market trading after dipping 62% on Monday.
- Trio Petroleum Corp. (NYSE: TPET) gained 19.3% to $0.1232 in pre-market trading after jumping over 21% on Monday.
- TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) shares rose 16.6% to $0.4799 in pre-market trading after declining 4% on Monday.
- Digital Health Acquisition Corp. (NASDAQ: DHAC) climbed 15.8% to $14.25 in pre-market trading after gaining 5% on Monday.
- HWH International Inc. (NASDAQ: HWH) shares rose 11.1% to $1.05 in pre-market trading after falling 5% on Monday.
- SolarMax Technology, Inc. (NASDAQ: SMXT) gained 9.1% to $11.95 in pre-market trading after jumping around 20% on Monday.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Losers- Acorda Therapeutics, Inc. (NASDAQ: ACOR) declined 58.7% to $5.50 in pre-market trading. Acorda Therapeutics said it will no longer hold its fourth quarter and year end 2023 earnings conference call originally scheduled for April 1. Acorda Therapeutics and Merz announced signing of "stalking horse" asset purchase agreement.
- Gritstone bio, Inc. (NASDAQ: GRTS) shares dropped 32.5% to $1.58 in pre-market trading after the company reported pricing of $32.5 million underwritten public offering.
- Canoo Inc. (NASDAQ: GOEV) fell 24.5% to $2.92 in pre-market trading. Canoo entered into a $30 billion market with multiple commercial vehicle sales in Saudi Arabia.
- Microvast Holdings, Inc. (NASDAQ: MVST) fell 24% to $0.6799 in pre-market trading after announcing fourth-quarter financial results.
- PVH Corp. (NYSE: PVH) fell 23.4% to $107.00 pre-market trading after the company reported fourth-quarter financial results and issued guidance.
- Aclarion, Inc. (NASDAQ: ACON) shares tumbled 21% to $0.3241 in pre-market trading after jumping 24% on Monday. Aclarion received a Notice of Allowance for its U.S. patent application 18/190,723 titled "Magnetic Resonance Spectroscopy Pulse Sequence, Acquisition, And Processing System And Method (For Diagnosing Pain)."
- Pioneer Power Solutions, Inc. (NASDAQ: PPSI) fell 20.2% to $4.74 pre-market trading after reporting unaudited preliminary financial results for the fourth quarter and 12 months ended Dec. 31, 2023.
- Avalo Therapeutics, Inc. (NASDAQ: AVTX) fell 18.1% to $14.66 in pre-market trading. Avalo Therapeutics shares fell around 18% on Monday after the company reported worse-than-expected FY23 EPS results.
- IM Cannabis Corp. (NASDAQ: IMCC) fell 16.4% to $0.6207 in pre-market trading after gaining 40% on Monday.
- GCT Semiconductor Holding, Inc. (NASDAQ: GCTS) shares fell 12.6% to $15.82 in pre-market trading after declining over 45% on Monday. GCT Semiconductor appointed Nelson C. Chan to Board of Directors.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Now Read This: Dave & Buster's Likely To Report Higher Q4 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.